Trials / Completed
CompletedNCT01143389
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Evaluation of Two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus or Ectasia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 510 (actual)
- Sponsor
- Price Vision Group · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
Detailed description
The primary objective of this study is to evaluate two riboflavin-dosing regimens for corneal collagen cross-linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive ectasia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riboflavin | Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea. |
| DEVICE | UVX light | UVX 365 nm wavelength light source is applied with continued application of riboflavin. |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2017-05-30
- Completion
- 2017-08-30
- First posted
- 2010-06-14
- Last updated
- 2018-06-06
- Results posted
- 2018-05-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01143389. Inclusion in this directory is not an endorsement.